Create account

Coverage dated October 13, 2026 to October 14, 2026

STAT+: FDA adcomm members’ ties to industry under scrutiny

Headline from STAT

New research found that nearly 40% of FDA advisory meetings held over a recent 20-year period included either a patient or consumer rep with active ties to an advocacy group…

STAT's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.

Read the reports

Reports & sources

2 articles, oldest first.

  1. STAT

    STAT+: Many patient, consumer reps on FDA advisory panels have ties to groups funded by pharma, analysis finds (opens STAT)

    Published

    STAT's feed description

    Nearly 40% of FDA advisory committee meetings over a 20-year period included either a patient or consumer rep with active ties to an advocacy group funded by pharma companies.

  2. STAT

    STAT+: FDA adcomm members’ ties to industry under scrutiny (opens STAT)

    Published

    STAT's feed description

    New research found that nearly 40% of FDA advisory meetings held over a recent 20-year period included either a patient or consumer rep with active ties to an advocacy group…

STAT+: FDA adcomm members’ ties to industry under scrutiny | Since Then